CD70
| CD70 molecule | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | CD70 | ||||||
| Alt. symbols | CD27LG, TNFSF7 | ||||||
| NCBI gene | 970 | ||||||
| HGNC | 11937 | ||||||
| OMIM | 602840 | ||||||
| RefSeq | NM_001252 | ||||||
| UniProt | P32970 | ||||||
| Other data | |||||||
| Locus | Chr. 19 p13 | ||||||
| |||||||
CD70 (Cluster of Differentiation 70) is a ligand for CD27.
Clinical significance
The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.[1]
Drug development
ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies. It is being developed by the Belgian company arGEN-X. In December 2013 a first part of a phase 1b trial was completed. In January 2014 a safety and efficacy phase of the study started.[2]
Vorsetuzumab mafodotin is a CD70-targeted antibody-drug conjugate that started clinical trials for renal cell carcinoma.[3]
See also
References
- ^ Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC (2005). "Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas". Mol. Cancer Ther. 4 (12): 2037–44. doi:10.1158/1535-7163.MCT-05-0253. PMID 16373719.
- ^ "ARGX-110: first-in-class CD70-targeting antibody with unique mode of therapeutic action". arGEN-X. Retrieved 28 February 2015.
- ^ Seattle Genetics Third Quarter 2013 Financial Report
External links
- CD70+Antigens at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
 | This membrane protein–related article is a stub. You can help Wikipedia by expanding it. |